BCL inhibitors treating platelet excess
A compound, methyl technology, applied in the field of BCL inhibitors for the treatment of excessive platelets, can solve problems such as deterioration
Inactive Publication Date: 2013-11-06
ABBVIE INC
View PDF2 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0003] Although circulating platelet production is a common physiological process, some diseases can be caused or exacerbated by excessive or undesired activation of platelets
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0919] 3-((Chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene- 1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl )amino)benzenesulfonamide
Embodiment 2
[0921] N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl )benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoro Methyl)sulfonyl)benzenesulfonamide
Embodiment 3
[0923] N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzyl Acyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl) Benzenesulfonamide
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.
Description
technical field [0001] The present invention encompasses methods of reducing platelet numbers in mammals and preventing or treating prothrombotic conditions and diseases characterized by excessive or undesired activation of platelets using anti-apoptotic Inhibitors of members of the Bcl-2 family of proteins. Background technique [0002] Platelets are enucleated blood cells derived from megakaryocytes that are essential for proper hemostasis and thrombus formation. Apoptosis-like processes are also associated with platelet biogenesis (ie, platelet production) and aging (ie, old age). The process of apoptosis has been extensively studied in nucleated cells; however, its role in enucleated cells has been less addressed. Cytochrome c, caspase-9, caspase-3, and APAF-1 have been reported to be expressed in platelets, suggesting that platelets contain the essential apoptotic machinery to execute programmed cell death. Several studies have shown that Bcl-2 family proteins (i.e....
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5377A61K31/495A61K31/496A61P7/02A61P9/00A61P35/02
CPCA61K31/495A61K31/00A61K31/496A61K31/5377A61P35/02A61P43/00A61P7/00A61P7/02A61P9/00A61P9/10
Inventor S·W·埃尔莫尔S·罗森伯格G·戈顿
Owner ABBVIE INC
